Apollo Endosurgery, Inc. Reports Third Quarter 2020 Results
Apollo Endosurgery (NASDAQ:APEN) reported a 21% increase in total Endoscopy revenue for Q3 2020, reaching $12.5 million, driven by a resurgence in elective procedures as COVID-19 restrictions eased. U.S. Endoscopy sales rose 37% to $6.6 million, with improved gross margins at 55% compared to 48%70% to $2.6 million. Cash and equivalents totaled $38.2 million as of September 30, 2020. Apollo aims to leverage liquidity through 2021 while completing clinical trials and launching new products.
- 21% increase in total Endoscopy revenue to $12.5 million.
- U.S. Endoscopy sales up 37% to $6.6 million.
- Gross margin improved to 55% from 48% year-over-year.
- Net loss decreased by 70% to $2.6 million.
- Cash and cash equivalents totaled $38.2 million.
- None.
Global Endoscopy Product Sales Increase
Conference Call to Discuss Results Today at 3:30 p.m. CT / 4:30 p.m. ET
AUSTIN, TX / ACCESSWIRE / November 5, 2020 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced financial results for the third quarter ended September 30, 2020.
Third Quarter 2020 and Recent Highlights
- Total Endoscopy revenue increased
21% compared to the third quarter of 2019 to$12.5 million - U.S. Endoscopy revenue increased
37% compared to the third quarter of 2019 to$6.6 million - Gross margin increased to
55% compared to48% in the third quarter of 2019 - Net loss improved by
70% to$2.6 million compared to$8.7 million for the third quarter of 2019 - Ended the quarter with
$38.2 million in cash, cash equivalents and restricted cash
"The third quarter rebound in elective procedures in our direct markets was both quicker and stronger than our early expectations," stated Todd Newton, Apollo's Chief Executive Officer. "We also took steps in the third quarter to lower our annual operating expenses and improve our liquidity position. As a result, we believe our liquidity provides sufficient runway through 2021 and through the COVID-19 pandemic, completion of the MERIT trial, and launch of X-Tack."
Third Quarter Results
Worldwide Endoscopy product sales were
Geographically, U.S. Endoscopy sales increased
By product group, U.S. ESS product sales increased
Total revenue for the third quarter of 2020 was
Gross margin increased to
Total operating expenses decreased
Net loss for the third quarter of 2020 was
Cash, cash equivalents and restricted cash were
Conference Call
Apollo will host a conference call on November 5, 2020 at 3:30 p.m. Central Time / 4:30 p.m. Eastern Time to discuss operating results for the third quarter ended September 30, 2020. To join the conference call by telephone, please dial +1-785-424-1667. A live webcast of the conference call will be made available on the "Events and Presentations" section of our Investor Relations website: ir.apolloendo.com.
A replay of the webcast will be made available on Apollo's website, www.apolloendo.com following the event.
Non-GAAP Financial Measures
To supplement our financial results, we are providing a non-GAAP financial measure, Endoscopy product sales percentage change in constant currency, which removes the impact of changes in foreign currency exchange rates that affect the comparability and trend of our Endoscopy product sales compared to the same period of the prior year. Endoscopy product sales percentage change in constant currency is calculated by translating current foreign currency sales at last year's exchange rate. This supplemental measure of our performance is not required by, and is not determined in accordance with GAAP.
We believe the non-GAAP financial measure included herein is helpful in understanding our current financial performance. We use this supplemental non-GAAP financial measure internally to understand, manage and evaluate our business, and make operating decisions. We believe that making non-GAAP financial information available to investors, in addition to GAAP financial information, may facilitate more consistent comparisons between the company's performance over time with the performance of other companies in the medical device industry, which may use similar financial measures to supplement their GAAP financial information. However, our non-GAAP financial measure is not meant to be considered in isolation or as a substitute for the comparable GAAP metric.
About Apollo Endosurgery, Inc.
Apollo Endosurgery, Inc. is a medical technology company focused on less invasive therapies to treat various gastrointestinal conditions, ranging from gastrointestinal complications to the treatment of obesity. Apollo's device-based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. Apollo's products are offered in over 75 countries today and include the OverStitch™ Endoscopic Suturing System, the OverStitch Sx™ Endoscopic Suturing System, and the ORBERA® Intragastric Balloon.
Apollo's common stock is traded on the Nasdaq Global Market under the symbol "APEN". For more information regarding Apollo Endosurgery, go to: www.apolloendo.com.
Cautionary Note on Forward-Looking Statements
Certain statements in this press release are forward-looking statements that are subject to risks and uncertainties that could cause results to be materially different than expectations. In addition, there is uncertainty about the spread of the COVID-19 virus and the impact it may have on the Company's operations, the demand for the Company's products, the Company's liquidity position, global supply chains and economic activity in general. Important factors that could cause actual results to differ materially include: the advancement of Apollo products; development of enhancements to Apollo's existing products and technologies; market acceptance of Apollo's products; the execution of our gross margin improvement projects; the ability to collect future payments from ReShape; statements relating to the availability of cash for Apollo's future operations; and Apollo's ability to support the adoption of its products and broaden its product portfolio as well as other factors detailed in Apollo's periodic reports filed with the Securities and Exchange Commission, or SEC, including its Form 10-K for the year ended December 31, 2019 and its Form 10-Q for the period ending September 30, 2020. Copies of reports filed with the SEC are posted on Apollo's website and are available from Apollo without charge. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, Apollo disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.
Disclosure Information
Apollo uses the investor relations section of its website as a means of complying with its disclosure obligations under Regulation FD. Accordingly, we recommend that investors should monitor Apollo's investor relations website in addition to following Apollo's press releases, SEC filings, and public conference calls and webcasts.
Contacts
Apollo Endosurgery, Inc.
Stefanie Cavanaugh, 512-279-5100
investor-relations@apolloendo.com
Darrow Associates Investor Relations
Matt Kreps, 214-597-8200
mkreps@darrowir.com
APOLLO ENDOSURGERY, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Operations
(In thousands, except for share data)
(unaudited)
Three Months Ended | Nine Months Ended | |||||||||||||||
2020 | 2019 | 2020 | 2019 | |||||||||||||
Revenues | $ | 12,826 | $ | 11,259 | $ | 29,188 | $ | 38,724 | ||||||||
Cost of sales | 5,840 | 5,826 | 14,136 | 18,884 | ||||||||||||
Gross margin | 6,986 | 5,433 | 15,052 | 19,840 | ||||||||||||
Operating expenses: | ||||||||||||||||
Sales and marketing | 4,178 | 6,495 | 12,773 | 21,995 | ||||||||||||
General and administrative | 2,374 | 3,159 | 7,870 | 10,219 | ||||||||||||
Research and development | 1,522 | 2,128 | 5,484 | 8,245 | ||||||||||||
Amortization of intangible assets | 486 | 510 | 1,472 | 1,591 | ||||||||||||
Settlement gain | - | - | - | (5,609) | ||||||||||||
Total operating expenses | 8,560 | 12,292 | 27,599 | 36,441 | ||||||||||||
Loss from operations | (1,574) | (6,859) | (12,547) | (16,601) | ||||||||||||
Other expenses: | ||||||||||||||||
Interest expense, net | 1,335 | 1,221 | 3,895 | 2,849 | ||||||||||||
Other (income) expense, net | (353) | 498 | 2,574 | 655 | ||||||||||||
Net loss before income taxes | (2,556) | (8,578) | (19,016) | (20,105) | ||||||||||||
Income tax expense | 41 | 80 | 90 | 131 | ||||||||||||
Net loss | $ | (2,597) | $ | (8,658) | $ | (19,106) | $ | (20,236) | ||||||||
Net loss per share, basic and diluted | $ | (0.11) | $ | (0.40) | $ | (0.88) | $ | (0.93) | ||||||||
Weighted average common shares outstanding, basic and diluted | 23,110,524 | 21,401,044 | 21,798,336 | 21,743,218 | ||||||||||||
APOLLO ENDOSURGERY, INC. AND SUBSIDIARIES
Product Sales by Product Group and Geographic Market
Unaudited (In thousands)
Three Months Ended | Three Months Ended | % Increase / (Decrease) | |||||||||||||||||||||||||||||||
U.S. | OUS | Total Revenues | U.S. | OUS | Total Revenues | U.S. | OUS | Total Revenues | |||||||||||||||||||||||||
ESS | $ | 4,734 | $ | 2,928 | $ | 7,662 | $ | 3,711 | $ | 2,949 | $ | 6,660 | 27.6 | % | (0.7) | % | 15.0 | % | |||||||||||||||
IGB | 1,853 | 3,021 | 4,874 | 1,088 | 2,633 | 3,721 | 70.3 | % | 14.7 | % | 31.0 | % | |||||||||||||||||||||
Total Endoscopy | 6,587 | 5,949 | 12,536 | 4,799 | 5,582 | 10,381 | 37.3 | % | 6.6 | % | 20.8 | % | |||||||||||||||||||||
% Endoscopy | 52.5 | % | 47.5 | % | 46.2 | % | 53.8 | % | |||||||||||||||||||||||||
Surgical | - | - | - | - | 640 | 640 | - | % | (100.0) | % | (100.0) | % | |||||||||||||||||||||
Other (1) | 272 | 18 | 290 | 228 | 10 | 238 | 19.3 | % | 80.0 | % | 21.8 | % | |||||||||||||||||||||
Total revenues | $ | 6,859 | $ | 5,967 | $ | 12,826 | $ | 5,027 | $ | 6,232 | $ | 11,259 | 36.4 | % | (4.3) | % | 13.9 | % | |||||||||||||||
(1) Other U.S. revenue includes
Nine Months Ended | Nine Months Ended | % Increase / (Decrease) | |||||||||||||||||||||||||||||||
U.S. | OUS | Total Revenues | U.S. | OUS | Total Revenues | U.S. | OUS | Total Revenues | |||||||||||||||||||||||||
ESS | $ | 10,873 | $ | 7,211 | $ | 18,084 | $ | 10,498 | $ | 10,339 | $ | 20,837 | 3.6 | % | (30.3) | % | (13.2) | % | |||||||||||||||
IGB | 3,511 | 6,688 | 10,199 | 4,005 | 8,552 | 12,557 | (12.3) | % | (21.8) | % | (18.8) | % | |||||||||||||||||||||
Total Endoscopy | 14,384 | 13,899 | 28,283 | 14,503 | 18,891 | 33,394 | (0.8) | % | (26.4) | % | (15.3) | % | |||||||||||||||||||||
% Endoscopy | 50.9 | % | 49.1 | % | 43.4 | % | 56.6 | % | |||||||||||||||||||||||||
Surgical | - | - | - | - | 3,670 | 3,670 | - | % | (100.0) | % | (100.0) | % | |||||||||||||||||||||
Other (1) | 854 | 51 | 905 | 1,632 | 28 | 1,660 | (47.7) | % | 82.1 | % | (45.5) | % | |||||||||||||||||||||
Total revenues | $ | 15,238 | $ | 13,950 | $ | 29,188 | $ | 16,135 | $ | 22,589 | $ | 38,724 | (5.6) | % | (38.2) | % | (24.6) | % | |||||||||||||||
(1) Other U.S. revenue includes
Non-GAAP Endoscopy product sales percentage change in constant currency were as follows:
Three Months Ended | Nine Months Ended | |||||||||||||
% Increase/Decrease in Constant Currency | % Increase/Decrease in Constant Currency | |||||||||||||
OUS | Total Revenues | OUS | Total Revenues | |||||||||||
ESS | (1.0) | % | 14.9 % | (28.6) | % | (12.4) | % | |||||||
IGB | 12.6 % | 29.4 % | (21.1) | % | (18.3) | % | ||||||||
Total Endoscopy | 5.4 % | 20.1 % | (25.2) | % | (14.6) | % | ||||||||
SOURCE: Apollo Endosurgery, Inc.
View source version on accesswire.com:
https://www.accesswire.com/614787/Apollo-Endosurgery-Inc-Reports-Third-Quarter-2020-Results
FAQ
What are Apollo Endosurgery's Q3 2020 revenue results?
How did U.S. Endoscopy sales perform in Q3 2020?
What was the net loss for Apollo Endosurgery in Q3 2020?
What was the gross margin for Apollo Endosurgery in Q3 2020?
What is the cash position of Apollo Endosurgery as of September 30, 2020?
